BioMedNewsBreaks

TuesdayNov 30, 2021 1:08 pm

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Key FDA Approvals, Participation in Psychedelics Conference

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has received authorization from the U.S. Food and Drug Administration (“FDA”) for an investigator-initiated, randomized, placebo-controlled phase 2 clinical trial; the trial is designed to evaluate psychedelic-assisted psychotherapy with psilocybin for frontline clinicians experiencing COVID-related distress. The company noted that the primary investigator for the trial, Dr. Anthony Back, received an investigational new drug ("IND") approval letter from the FDA, authorizing the trial. In addition, the study has received Institutional Review Board (“IRB”) approval at the University of Washington. Cybin also announced that CEO Doug Drysdale…

Continue Reading

TuesdayNov 30, 2021 12:11 pm

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) CEO to Present at Benzinga Global Small Cap Conference

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that its CEO Faz Chowdhury, Ph.D., will present at the Benzinga Global Small Cap Conference. The event is scheduled to be held virtually from Dec. 8-9, 2021. Dr. Chowdhury will deliver his corporate presentation at 3:00 p.m. ET on Dec. 8 and will be available for one-on-one meetings throughout the conference. Interested parties should visit https://ibn.fm/puHmj to register for the event. To view the full press release, visit https://ibn.fm/P72Au About Nemaura Medical Inc. Nemaura Medical…

Continue Reading

TuesdayNov 30, 2021 11:41 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Advances Strategy Toward Potential Therapeutics for Diseases with High Unmet Needs

InMed Pharmaceuticals (NASDAQ: INM) recently filed a Patent Cooperation Treaty (“PCT”) application, which specifies a rare cannabinoid (new to InMed’s portfolio) that may inhibit or slow the progression of neurogenerative diseases – such as Alzheimer’s, Parkinson’s, Huntington’s and others – by providing protection in a population of affected neurons. Furthermore, the application demonstrates the cannabinoid can also be used to promote neurite outgrowth, signifying the potential to enhance neuronal function. According to InMed’s Senior VP Pre-Clinical Research & Development Dr. Eric Hsu, who is quoted in a recent article, “This PCT patent application advances our strategy directed towards researching and…

Continue Reading

MondayNov 29, 2021 11:49 am

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes Adelia Milestone Achievements

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has reported that its wholly controlled subsidiary, Adelia Therapeutics Inc., has achieved key milestones. The milestones were outlined in the agreement between Cybin, Cybin Corp., Cybin US Holdings Inc. and the previous shareholders of Adelia. Based on the agreement, 31,721.5 class B common shares of the company will be issued to Adelia shareholders as a result of relevant milestones being met. Adelia develops medicinal psychedelics designed to provide improved dosing efficacy and therapeutic indices that address unmet medical needs. The company’s primary focus is on the…

Continue Reading

MondayNov 29, 2021 9:30 am

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Releases Financial, Operations Report for Latest Period

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, has reported its unaudited financial results and business highlights for the nine months ended Sept. 30, 2021. Financial highlights include total revenue reaching an estimated  $2.1 million, which is a 55.3% over the same period in 2020, and gross profit margin totaling 59.3%, representing an 8.8% increase from the year before. In addition, the average selling price of ANPC’s CDA-based tests was $71.6,  an increase of 72.3% from 2020. In addition, the company reported cash and cash…

Continue Reading

WednesdayNov 24, 2021 12:21 pm

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Looking to Change Narrative in Treating Fibromyalgia, Chronic Pain

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is looking to transform the existing treatment of fibromyalgia, along with other forms of chronic pain, and relieve the suffering of millions of patients. To achieve this, the company is relying on the guidance of its scientific advisory board (“SAB”) as well as research-based work conducted in partnership with the University of Michigan (“U-M”). “According to Tryp’s internal analysis, over 4 million people suffer from fibromyalgia in the United States. Globally, the condition affects an estimated 3-6% of the population (roughly 232-465 million people). Unfortunately, despite the disease afflicting millions, researchers have not yet…

Continue Reading

TuesdayNov 23, 2021 11:54 am

BioMedNewsBreaks – Avricore Health Inc.’s (TSX.V: AVCR) (OTCQB: AVCRF) HealthTab(TM) Enters Agreement to Support Patients with Key Insight into Renal Function

Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) today announced that its wholly owned subsidiary, HealthTab(TM), has entered into a non-exclusive, pilot supplier distribution agreement in Canada with Abbott, the global health care company, with respect to the handheld blood chemistry analyzer, i-STAT Alinity. Under the agreement, HealthTab will distribute Abbott’s point-of-care i-STAT Alinity and its associated tests for creatinine in Canadian pharmacies to better support patients with important information about their renal function. “Understanding renal function in patients at risk from or already living with chronic disease is critical,” said Hector Bremner, CEO of Avricore Health. “With i-STAT Alinity and its…

Continue Reading

ThursdayNov 18, 2021 11:47 am

BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) CEO Discusses Blockbuster Drug Potential on MidasLetter Podcast

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, was featured in a recent MidasLetter Live podcast. Mydecine’s CEO and Chairman Joshua Bartch joined the program to provide an overview of the company and the science behind its psychedelic compounds. “What we are showing in the efficacy rates that are coming out of that study are over three to five times what’s currently available of Chantix or a nicotine patch with a much safer drug,” Bartch said in discussing clinical trials for smoking cessation using…

Continue Reading

WednesdayNov 17, 2021 1:54 pm

BioMedNewsBreaks – Way2Grow Biopharma Corp. Enters ‘Next Phase of Life Science Therapeutics’

Way2Grow (“W2G”), a privately held therapeutic corporation existing under the laws of British Columbia, today announced approval of a Health Canada Dealer’s Licence Application. Under the approval, Health Canada issued notice to W2G to complete the construction of a level 8 secure environ and psilocybin production campus. The license and production facility will allow W2G to procure psychedelics as well as propagate, cultivate, harvest and sell psychedelics to pharmacies, clinics and other licenced research facilities for allowable research purposes pursuant to the Controlled Drugs and Substances Act (the “CDSA”). “We are excited to enter this next phase of life science…

Continue Reading

WednesdayNov 17, 2021 11:11 am

BioMedNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Featured in ROTH Equity Research Report

Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “We are reiterating our Buy rating and C$3/share 12-month price target on Mydecine following the release of 3Q21 results. . . The highlight of the quarter was the announcement that Mydecine plans to continue clinical research that was initiated a number of years ago at Johns Hopkins University, under the leadership of Dr. Matthew Johnson, a world-renowned psychedelic drug researcher. In a small, preliminary, open-label pilot study (n=15), it was shown that 80% of the subjects…

Continue Reading